FindTrial
Sign In

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab

DRUG2 trials

Sponsors

Takeda

Conditions

Colorectal Cancer

Phase 3

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
CompletedNCT02394795
TakedaColorectal Cancer
Start: 2015-05-29End: 2022-01-14Updated: 2023-11-01

Unknown Phase

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Active, not recruitingNCT02394834
TakedaColorectal Cancer
Start: 2015-05-29End: 2027-09-30Updated: 2026-04-13

Related Papers

ctDNA dynamics and prognostic value during first-line treatment of metastatic colorectal cancer: Analysis from the phase 3 PARADIGM study.
Journal of Clinical Oncology2026-05-27
Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.
Journal of Clinical Oncology2024-06-013 citations
Abstract 5844: Landscapes of acquired EGFR and VEGF resistance alterations in colorectal cancer: findings from the PARADIGM biomarker study
Cancer Research2024-03-22
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer
Nature Medicine2024-02-1285 citations
First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with <i>HER2</i> amplification (<i>HER2</i>amp<i>+</i>), <i>RAS</i> wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.
JCO Global Oncology2023-08-01
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and <i>RAS</i>/<i>BRAF</i> WT: A biomarker study of the phase III PARADIGM trial.
Journal of Clinical Oncology2023-06-014 citations
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer
JAMA2023-04-18219 citations
Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.
Journal of Clinical Oncology2023-01-2433 citations
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Journal of Clinical Oncology2022-06-0866 citations
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.
Journal of Clinical Oncology2021-01-208 citations
Abstract 1974: Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study
Cancer Research2020-08-15
Development of oncogene panel for detecting predictive and prognostic factors of metastatic colorectal cancer
Annals of Oncology2018-10-01
Abstract CT164: Circulating tumor DNA analysis for predictive and prognostic factors in patients with metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study
Cancer Research2018-07-01
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
Clinical Colorectal Cancer2017-01-2412 citations
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.
Journal of Clinical Oncology2016-05-203 citations
PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.
Journal of Clinical Oncology2016-02-015 citations